Exelixis, Inc. (EXEL)
| Previous Close | 21.06 |
| Open | 21.01 |
| Bid | 21.08 x 100 |
| Ask | 21.11 x 100 |
| Day's Range | 20.89 - 21.19 |
| 52 Week Range | 18.64 - 24.34 |
| Volume | |
| Avg. Volume | 2,278,650 |
| Market Cap | 6.143B |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | 32.44 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
ALAMEDA, Calif., May 20, 2024--Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla). This settlement resolves two patent litigations brought by Exelixis in response to Cipla’s Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of CABOMETYX® (cabozantinib) tablets prior to the expiration of the applicable patents. The first case (Civil Action N
- Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
ALAMEDA, Calif., May 07, 2024--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May:
- Business Wire
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
ALAMEDA, Calif., April 30, 2024--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones.
